BiotechTube
Rarecells

Rarecells

Paris, France· Est.
rarecells.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Rarecells is a private, commercial-stage diagnostics company pioneering a next-generation liquid biopsy platform for the ultra-early detection of cancer. Its CE-IVD-certified ISET® technology isolates circulating tumor cells (CTCs) from blood with unparalleled sensitivity, capable of detecting a single tumor cell, and is being commercialized for cancer testing in Paris. The company's R&D strategy combines CTC-DNA analysis with circulating tumor DNA (ctDNA) and AI-driven multiomics to significantly enhance detection sensitivity and genomic insight, aiming to set a new global standard in precision oncology and early intervention.

Oncology

Technology Platform

ISET® (Isolation by Size of Epithelial Tumor Cells) platform: A marker-agnostic, filtration-based liquid biopsy technology that isolates circulating tumor cells (CTCs) from blood based on physical size. The platform is being enhanced with combined CTC-DNA and circulating tumor DNA (ctDNA) analysis, multiomics, and AI to achieve ultra-high sensitivity for early cancer detection.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

The massive, unmet need for early cancer detection represents a multi-billion dollar market.
Rarecells' technology, which claims to detect cancer years before imaging, could redefine screening paradigms and capture significant value as the first mover in 'pre-imaging' diagnosis.
Success could position the company as a gateway to the entire oncology care pathway.

Risk Factors

Key risks include the need for large-scale clinical trials to prove mortality benefit, the challenge of securing reimbursement for a new screening test, and intense competition from well-funded rivals in the multi-cancer early detection space.
Scaling from a Paris-based service to a global product also presents significant execution risk.

Competitive Landscape

Rarecells operates in the highly competitive liquid biopsy space, facing large rivals like Grail (Illumina), Guardant Health, and Exact Sciences that are developing multi-cancer early detection (MCED) tests primarily based on ctDNA methylation. Rarecells differentiates by using a physical CTC isolation method (ISET®) combined with ctDNA, claiming superior sensitivity, but must prove this advantage in head-to-head clinical and commercial settings.

More companies in Diagnostics & Precision Medicine →More companies in France →